Serum prolactin levels in psoriasis and correlation with cutaneous disease activity

Dilmé-Carreras, E.; Martín‐Ezquerra, Gemma; Sánchez‐Regaña, M.; Umbert-Millet, P.

doi:10.1111/j.1365-2230.2010.03871.x

Cited by 25 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22,31,32 ). More recent publications have demonstrated the positive correlation between PASI score and serum PRL levels in 20 and 23 patients with PV treated with tacalcitol 21 and propylthiouracil 33 , respectively, and the serum PRL levels were increased in both studies in PV patients compared to healthy individuals. However, two recent studies with 30 PV patients did not detect hyperprolactinemia or elevated PRL levels compared to healthy controls 34,35 and although PRL levels decreased after treatment of newly diagnosed PV, no correlation with PASI was found 35 .…”

Section: Discussionmentioning

confidence: 74%

“…30% of patients were treated by biologics. This is in contrast to Dilmé-Carreras 21 and Malligarjunan 33 as in these studies, systemic and topical treatment was unwarranted before enrollment. While PRL release can be influenced by chronic emotional stress 36 and PV is recognised as a disease with a psychological component, the small differences in treatment might have an impact on the perception of the disease and levels of psychological stress.…”

Section: Discussionmentioning

confidence: 78%

“…PRL is overexpressed in psoriatic skin lesions 20 . Dilmé-Carreras found a positive correlation between serum PRL levels and the corresponding index PASI (psoriasis area and severity index) after tacalcitol treatment 21 . Conversely, bromocriptine as a drug that downregulates PRL pituitary release was found to be effective in PsA treatment 22 .…”

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris

Hušáková¹,

Lippert²,

Štolfa³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

a Background and Aims. Psoriasis vulgaris (PV) is complicated in up to 40% patients by the inflammatory joint disease psoriatic arthritis (PsA). Neither the aetiology of the arthritis nor specific laboratory markers for its disease activity have been clearly elucidated. Prolactin (PRL) acts as a cytokine with immunomodulatory functions and plays a role in skin and joint biology. The results on PRL however as a marker are unclear. The aim of this study was to confirm whether serum PRL levels reflect systemic complications of PV, like inflammatory joint disease and/or can serve as a marker of disease activity in both cases. Methods. A total of 70 patients with PV without arthritis and 40 patients suffering from PsA were included. In all patients, we determined skin disease activity according to the PASI index and in PsA, active disease assessed as swollen or tender joints. The control group included 27 age and sex matched healthy individuals. The concentration of PRL in the serum was measured by immunoradiometric assays. Results. The PRL serum levels were significantly increased in PsA patients (299.2±28.29 mIU/L) compared to PV only patients (201.4.2±11.72 mIU/L), P = 0.0003 and healthy individuals (198.2±15.31 mIU/L), P = 0.007. The serum PRL levels in PsA with active disease 336.8±42.50 (mIU/L) were higher than in PV and controls, P < 0.0001 and P = 0.002 respectively. In PV only patients, there was no correlation between PASI and PRL levels. Conclusion. Our results showed that PRL serum levels are a marker of active arthritis in PsA and reflects systemic complication rather than local skin activity.

show abstract

Section: Discussionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 78%

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris

Hušáková¹,

Lippert²,

Štolfa³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…Indeed, these findings correspond well to an earlier study that had shown a positive association between raised serum PRL levels and psoriasis. An intriguing new dimension in the Dilme-Carreras et al [3] study was the finding that clinical improvement in psoriasis, in response to treatment with topical tacalcitol, was accompanied by a decrease in serum PRL level, and that there was a correlation between serum PRL level and clinical severity as assessed by PASI score. Comparing the results of this study with the results of the present study have showed increased serum prolactin level in the studied group of patients with plaque-type psoriasis vulgaris and decrease of this level after 3 months period of treatment with NB-UVB.…”

Section: Discussionmentioning

confidence: 99%

“…Dilme-Carreras et al [3] carried out a study on 20 patients with plaque-type psoriasis before and after a 6-weeks period of topical treatment. Results were compared with a group of 20 healthy volunteers.…”

Section: Discussionmentioning

confidence: 99%

Serum Prolactin and ImmunoglobulinE Levels in Psoriasis Vulgaris before and after NB-UVB Therapy

Shalaby¹

2015

Med chem

View full text Add to dashboard Cite

The HLA-Cw*06 allele and −1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population

et al. 2012

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) affects approximately 30 % of patients suffering from psoriasis vulgaris (PsV), but the risk factors for its development have not been well elucidated yet. The HLA-Cw*06 allele was described as a predisposing factor to PsV. Prolactin is known as an immune response modulator, and its elevated levels present risk for PsV development. It is possible that these factors interact and together emphasize the predisposition to both diseases. We tested on an association of HLA-Cw alleles and functional polymorphism -1149 G/T in PRL gene extrapituitary promoter with PsV and PsA in Czech population. We found a statistically significant association between HLA-Cw*06 allele and PsV (P corrected = 0.0013) that was most prominent in early onset disease subtype (P corrected = 0.0013). The association between HLA-Cw*06 and PsA was low (P corrected = 0.0585) and restricted to PsA patients with early PsV onset (P corrected = 0.0195). We found no association of -1149 G/T PRL gene polymorphism with either PsV or PsA.

show abstract

Serum prolactin levels in psoriasis and correlation with cutaneous disease activity

Abstract: These results indicate that serum PRL levels may serve as a biological marker of psoriatic disease activity.

Cited by 25 publications

References 18 publications

Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris

Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris

Serum Prolactin and ImmunoglobulinE Levels in Psoriasis Vulgaris before and after NB-UVB Therapy

The HLA-Cw*06 allele and −1149 G/T polymorphism of extrapituitary promoter of PRL gene as a possible common genetic predisposing factors to psoriasis vulgaris and psoriatic arthritis in Czech population

Contact Info

Product

Resources

About